Effectiveness of nalbuphine, a κ-opioid receptor agonist and μ-opioid receptor antagonist, in the inhibition of INa, IK(M), and IK(erg) unlinked to interaction with opioid receptors

被引:10
|
作者
Liu, Yuan-Yuarn [1 ]
Hsiao, Hung-Tsung [2 ]
Wang, Jeffery C. -F. [2 ]
Liu, Yen-Chin [2 ]
Wu, Sheng-Nan [3 ,4 ]
机构
[1] Kaohsiung Vet Gen Hosp, Div Trauma, Dept Emergency, Kaohsiung, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Anesthesiol, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan
[4] Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 70101, Taiwan
关键词
delayed-rectifier K+ current; erg-mediated K+ current; hippocampal neuron; M-type K+ current; nalbuphine; opioid receptor; voltage-gated Na+ current; CHANNELS; CELLS; TEFLUTHRIN; ACTIVATION; MORPHINE; ALPHA; STAGE;
D O I
10.1002/ddr.21568
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nalbuphine (NAL) is recognized as a mixer with the kappa-opioid receptor agonist and the mu-opioid receptor antagonist. However, whether this drug causes any modifications in neuronal ionic currents is unclear. The effects of NAL on ionic currents in mHippoE-14 hippocampal neurons were investigated. In the whole-cell current recordings, NAL suppressed the peak amplitude of voltage-gated Na+ current (I-Na) with an IC50 value of 1.9 mu M. It shifted the steady-state inactivation curve of peak I-Na to the hyperpolarized potential, suggesting that there is the voltage dependence of NAL-mediated inhibition of peak I-Na. In continued presence of NAL, subsequent application of either dynorphin A(1-13) (1 mu M) or naloxone (30 mu M) failed to modify its suppression of peak I-Na. Tefluthrin (Tef; 10 mu M), a pyrethroid known to activate I-Na, increased peak I-Na with slowed current inactivation; however, further application of NAL suppressed Tef-mediated suppression of peak I-Na followed by an additional slowing of current inactivation. In addition, NAL suppressed the amplitude of M-type K+ current [I-K(M)] with an IC50 value of 5.7 mu M, while it slightly suppressed erg-mediated and delayed-rectifier K+ currents. In the inside-out current recordings, NAL failed to modify the activity of large-conductance Ca2+-activated K+ channels. In differentiated NG108-15 neuronal cells, NAL also suppressed the peak I-Na, and subsequent addition of Tef reversed NAL-induced suppression of I-Na. Our study highlights the evidence that in addition to modulate opioid receptors, NAL has the propensity to interfere with ionic currents including I-Na and I-K(M), thereby influencing the functional activities of central neurons.
引用
收藏
页码:846 / 856
页数:11
相关论文
共 44 条
  • [1] Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy μ opioid receptor agonist and a δ opioid receptor antagonist
    Mada, Sanjana
    Gerak, Lisa R.
    Soyer, Amelie
    Maguire, David R.
    Hu, Zehua
    Minervini, Vanessa
    Cunningham, Christopher W.
    France, Charles P.
    PSYCHOPHARMACOLOGY, 2020, 237 (12) : 3591 - 3602
  • [2] Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis
    Inan, Saadet
    Huerta, Alvaro T.
    Jensen, Liselotte E.
    Dun, Nae J.
    Cowan, Alan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 864
  • [3] The Evidence for Sparsentan-Mediated Inhibition of INa and IK(erg): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor
    Chuang, Tzu-Hsien
    Cho, Hsin-Yen
    Wu, Sheng-Nan
    BIOMEDICINES, 2022, 10 (01)
  • [4] Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist
    Levy-Cooperman, N.
    McIntyre, G.
    Bonifacio, L.
    McDonnell, M.
    Davenport, J. M.
    Covington, P. S.
    Dove, L. S.
    Sellers, E. M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 359 (03) : 471 - 481
  • [5] The δ Opioid Receptor Agonist SNC80 Selectively Activates Heteromeric μ-δ Opioid Receptors
    Metcalf, Matthew D.
    Yekkirala, Ajay S.
    Powers, Michael D.
    Kitto, Kelley F.
    Fairbanks, Carolyn A.
    Wilcox, George L.
    Portoghese, Philip S.
    ACS CHEMICAL NEUROSCIENCE, 2012, 3 (07): : 505 - 509
  • [6] The μ-opioid receptor agonist morphine, but not agonists at δ- or κ-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors
    Pacheco, D. da Fonseca
    Klein, A.
    Perez, A. de Castro
    Pacheco, C. M. da Fonseca
    de Francischi, J. N.
    Duarte, I. D. G.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (05) : 1143 - 1149
  • [7] Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic
    Inan, Saadet
    Dun, Nae J.
    Cowan, Alan
    MOLECULES, 2021, 26 (18):
  • [8] Bisoprolol, Known to Be a Selective 1-Receptor Antagonist, Differentially but Directly Suppresses IK(M) and IK(erg) in Pituitary Cells and Hippocampal Neurons
    So, Edmund Cheung
    Foo, Ning-Ping
    Ko, Shun Yao
    Wu, Sheng-Nan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03):
  • [9] In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
    Guillemyn, Karel
    Kleczkowska, Patrycja
    Novoa, Alexandre
    Vandormael, Bart
    Van den Eynde, Isabelle
    Kosson, Piotr
    Asim, Muhammad Faheem
    Schiller, Peter W.
    Spetea, Mariana
    Lipkowski, Andrzej W.
    Tourwe, Dirk
    Ballet, Steven
    MOLECULAR BRAIN, 2012, 5
  • [10] Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands
    Bender, Aaron M.
    Clark, Mary J.
    Agius, Michael P.
    Traynor, John R.
    Mosberg, Henry I.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (02) : 548 - 551